NCT04346914View on ClinicalTrials.gov

Study of ZKAB001 Combined With Carboplatin and Etoposide in the Extensive Small Cell Lung Cancer

PHASE1UnknownINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

March 8, 2020

Primary Completion Date

October 30, 2022

Study Completion Date

October 30, 2022

Conditions
Extensive Stage Small Cell Lung Cancer
Interventions
BIOLOGICAL

recombinant anti-PD-L1 monoclonal antibody injection combined with carboplatin and etoposide

ZKAB001 ,5 mg/kg, d1，q3w； carboplatin，5 AUC，d1，q3w； etoposide，100mg/m2，d1\~3，q3w

Trial Locations (1)

021

RECRUITING

Shanghai Chest Hospital, Shanghai

Sponsors
All Listed Sponsors
lead

Lee's Pharmaceutical Limited

INDUSTRY